Role of Tyrosine Kinases in Gastrointestinal Malignancies, Softcover reprint of the original 1st ed. 2018

The aim of this book is to provide comprehensive overview of the role of different tyrosine kinases in the progression and metastasis of various cancers of the gastrointestinal tract such as esophagus, liver, pancreas, stomach, and colorectal. Activation of various signaling pathways and tyrosine kinases are responsible for resistance to chemo and radiotherapy in these gastrointestinal malignancies. Targeting these tyrosine kinases, which regulate the activities of survival pathways in growth, and metastasis is a rational strategy in gastrointestinal cancer therapy.

Each chapter embedded in this book covers information pertaining to a specific tyrosine kinase and its impact on various malignancies, which is not only significant for basic and clinical research investigations but will also be valued by students at advanced undergraduate to postgraduate levels.

Chapter 1. 1.  Overview of tyrosine kinases and their receptors in gastrointestinal malignancies- .- Chapter 2. EGFR and Erb-B2R (HER2): their role in Esophagus cancer.- Chapter 3. HGFR and FGFR2: their role in progression and metastasis  of Esophagus cancer.- Chapter 4. Role of Src and VEGF R tyrosine kinases in Esophagus cancer.- Chapter  5. HGF receptor tyrosine kinase in gastric cancer. - Chapter  6. The EGF/ErbB receptor family of tyrosine kinases in gastric cancer.- Chapter  7. Helicobacter pylori CagA protein: its role and interaction tyrosine kinases in gastric cancer.- Chapter 8. RON receptor tyrosine kinase in pancreatic cancer progression.- Chapter 9. EGFR and Cytoplasmic kinases Src targeting in pancreatic cancer.- Chapter 10. VEGF and PDGFR targeting in pancreatic cancer.- Chapter 11. c-KIT, and FLT-3: their role in Hepatocellular carcinoma.- Chapter 12. VEGFR, and PDGFR: their targeting in Liver Cancer.- Chapter 13. EGFR and FGFR in growth and metastasis of colorectal cancer.- Chapter 14. VEGFR, and PDGFR: their targeting in colorectal cancerm.- Chapter 15. Nano materials and their impact on tyrosine kinase on selected gastrointestinal malignancies.- Chapter 16. Tyrosine kinase inhibitors and their clinical prospective in gastrointestinal malignancies.- Chapter 17. Drug resistance against tyrosine kinase inhibitors in gastrointestinal malignancies.- Chapter 18. Tyrosine kinases: their expression, diagnostic, therapeutic and prognostic aspects in gastrointestinal cancers.

Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He obtained his MSc and his Ph.D., both in biotechnology, from Sri Venkateswara University, Tirupati, Andhra Pradesh, India. His research focuses on translational projects related to gastrointestinal malignancies. He has published over 65 research articles in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. He has also served as an editorial board member of several internationally recognized academic journals. He is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He has received several prestigious international awards and holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), the Science Advisory Board, The RNA Society, and the American Association of Cancer Research (AACR).